肝炎病毒,戊型

摘要： 目的 分析2017年山东省戊型肝炎病毒(HEV)的基因型分布和分子流行病学特征.方法 选取山东省2017年1-12月通过国家法定传染病报告系统报告的戊型肝炎病例为研究对象,对其进行个案调查,并采集其血清标本,共1 045例.采用酶联免疫吸附试验(ELISA)法复核检测HEV-IgM和HEV-IgG抗体,对HEV-IgM阳性者的血清提取病毒核酸,采用逆转录PCR方法扩增HEV开放式阅读框架2区域内长度为644 bp的核苷酸片段,直接测序后与GenBank下载的参考病毒株序列进行同源性和系统进化分析.结果 HEV-IgM复核检测阳性者638例(61.1％),其中男性病例年龄为(57.9±12.2)岁,阳性率为61.5％ (496/807),女性病例年龄为(58.1±15.O)岁,阳性率为59.7％(142/238);复核检测阳性者中共检出163株HEV毒株,检出率为25.6％(163/638),其中,东、中和西部地区检出率分别为23.0％(71/309)、33.6％ (72/214)和17.4％ (20/115).检出的163株HEV病毒株均属于基因Ⅳ型,以4d亚型为主,占85.9％(140株),其次为4b亚型(7.4％,12株),以及少量的4a和4h亚型,分别占3.7％(6株)和3.1％(5株).4a、4b和4h基因亚型组病例以东部为主,分别占3/5、11/12和4/6;4d基因亚型组以中部为主,占50.0％ (70/140).163株HEV的核苷酸序列同源性为82.7％～100.0％,其中140株HEV 4d亚型毒株与山东省猪源(KF176351)、牛源(KU904278)和羊源(KU904267)HEV毒株亲缘关系较近,核苷酸同源性分别为93.1％～98.3％、92.7％～97.9％和92.7％～97.9％.结论 山东省HEV优势流行株属于基因Ⅳ型4d亚型,跨种间传播可能是山东省人HEV感染的主要来源.

摘要： 目的 分析中国戊型肝炎流行病学特征,为防控戊型肝炎提供参考.方法 2004-2017年戊型肝炎发病数据来源于中国疾病预防控制中心“传染病报告信息管理系统”,不含中国香港、澳门、台湾数据,按照发病日期下载数据.戊型肝炎突发公共卫生事件来源于“突发公共卫生事件管理信息系统”,报告标准依据《国家突发公共卫生事件相关信息报告管理工作规范(2006版试行)》.将发病数据分为2004-2007、2008-2011和2012-2017年3个时段,分别代表戊型肝炎疫苗上市前8年、疫苗上市前4年和疫苗上市后.采用线性回归对发病率进行趋势性分析,采用改良的集中度M值分析法分析季节性特征,计算集中度M值.结果 2004-2017年,中国累计报告329 519例戊型肝炎病例,报告发病率由1.27/10万上升至2.10/10万,呈逐渐上升趋势(t=6.87,P＜0.001).2004-2007、2008-2011、2012-2017年戊型肝炎集中度M值分别为17.43、16.06、11.17,季节性较弱.江苏、广东和浙江报告发病数占全国病例数的31.54％.东部报告发病率为2.67/10万,高于中部(1.45/10万)、西部(1.11/10万),但中部、西部报告发病率持续升高.报告发病率随年龄增长而升高(t=7.85,P＜0.001),≥40岁人群报告发病率＞2/10万,65～69岁最高(5.22/10万).农民、离退休人员、家政/家务及待业报告病例数占总报告病例数的67.46％.戊型肝炎突发公共卫生事件共报告7起,其中敬老院报告3起.结论 中国中部、西部戊型肝炎报告发病率持续升高,需加强中、西部地区戊型肝炎监测;中老年人群、农民及敬老院等集体单位发病风险高.%Objective To analyze the changing epidemiological characteristics of hepatitis E cases in China,in order to promote in preventing and controlling hepatitis E.Methods Data of hepatitis E and outbreaks reported through national notifiable diseases reporting system were analyzed from 2004 to 2017,but data of Hongkong,Macau and Taiwan were not included.Data of hepatitis E were divided into three phases as 2004-2007,2008-2011 and 2012-2017,representing eight years before,four years before and years after the postmarketing of hepatitis E vaccine.Linear regression was used for analyzing the trend of hepatitis E,improved muster method was used for analyzing the seasonal intensity.Results From 2004 to 2017,329 519 hepatitis E cases were reported and the annual incidence were increasing from 1.27/100000 to 2.10/100 000 (t=6.87,P＜0.001).The concentrations of hepatitis E during 2004-2007,2008-2011 and 2012-2017 were 17.43,16.06,11.17,respectively,with low seasonal intensity.Number of cases reported by Jiangsu,Guangdong and Zhejiang accounted for 31.54％ of national cases.The incidence were lower in central (1.45/100 000) and western (1.11/100 000) region than that in eastern region (2.67/100 000),but were increasing continuously.There was an increasing trend of incidence with growing ages (t=7.85,P＜0.001).The incidence was higher than 2/100 000 among cases aged ≥40,and was the highest (5.22/100 000) in the age group of 65-69 years old.Farmers,retired persons,houseworkers and unemployees accounted for 67.46％ of total cases.A total of 7 outbreaks were reported,among which 3 were in nursing homes.Conclusion The incidence of hepatitis E in central and western regions were increasing continuously and the surveillance should be strengthened.There was higher risk among middle-aged population,farmers and nursing homes,so strategy for immunization among those population was in great need.

摘要： 戊型肝炎病毒(HEV)感染可导致急、慢性病毒性肝炎和肝功能衰竭,同时与一系列肝外表现相关.神经系统损害是HEV感染最常见的肝外表现之一.近年来,关于戊型肝炎神经系统并发症的病例报道逐渐增多.吉兰-巴雷综合征和神经痛性肌萎缩是戊型肝炎病毒感染相关的主要的神经系统表现.急性戊型肝炎的神经系统并发症发病机制尚未明确.目前研究主要集中在病毒感染引起的免疫应答与病毒的直接作用两方面.本文对戊型肝炎病毒引起的神经系统表现及可能的发病机制进行综述.%Hepatitis E virus (HEV) infection could cause acute or chronic hepatitis and liver failure and is associated with a number of extrahepatic manifestations. Neurological injuries were one kind of the most common extrahepatic manifestations of HEV infection. In recent years, case reports on hepatitis E neurological complications increased gradually. Guillain-Barre syndrome and neuralgic amyotrophy were the main neurological manifestations associated with acute HEV infection. Pathogenesis of HEV related neurological manifestations were controversial. Current research focuses on immune mediated injury and HEV directly neurotropic injury. Hepatitis E virus associated neurological manifestations and possible pathogenesis were reviewed in this paper.

摘要： 戊型肝炎病毒(HEV)感染通常引起急性肝炎,疾病呈自限性发展过程,一般在6个月内临床康复,预后良好.近年来的研究发现,HEV感染在特殊情况下也可呈现出感染慢性化,表现为HEV急性感染后至少6个月仍存在肝功能的持续异常,且血清、粪便和(或)肝组织仍可检出病毒核酸.HEV感染慢性化主要发生于免疫功能不全者,临床不多见,但危害大.了解HEV感染慢性化的发生机制、临床表现、治疗及预防措施,有助于临床医师制定科学有效的管理方案,改善患者预后.现就相关问题进行介绍,以提高临床医师对该病的认识水平.%Hepatitis E virus (HEV) infection usually causes acute hepatitis and has a self-limiting progression.The patients often recover within 6 months with good prognosis.Recent studies have found that HEV infection may become chronic in special situations,which manifests as persistent liver function abnormalities for at least 6 months after acute HEV infection and the presence of viral nucleic acid in serum,feces,and/or liver tissue.Chronicity of HEV infection mainly occurs in immunocompromised patients,and it is rare but very dangerous in clinical practice.An understanding of the pathogenesis,clinical manifestations,treatment methods,and preventive measures of chronicity of HEV infection helps clinical physicians develop an effective management regimen and improve patient prognosis.This article introduces related issues,in order to raise the awareness of this disease among clinical physicians.

摘要： Objective To analyze the sero-epidemiological characteristics of hepatitis E virus (HEV) in Shandong province, and thereby to provide evidence for the policy-making of hepatitis E prevention and control. Methods The inhabitants aged between 1-59 years old were randomly selected to participate in the study by two-stage stratified random sampling method from 12 counties in Shandong province in October, 2014. Firstly two townships were selected from each county by probability proportional to size sampling (PPS) method. A total of 5229 participants aged 1-59 years old were selected by stratified random sampling method. All the participants finished a questionnaire survey and a venous blood sample (3-5 ml) was collected from each to test anti-HEV IgG by enzyme-linked assay (ELISA). The weighted prevalence of anti-HEV IgG with different demographic characteristics was estimated. The variance of the positive rate of anti-HEV IgG was calculated by Taylor series linearization method, as well as its 95%CI. A statistical test was conducted to compare the rate of its 95%CI, and the results in the present study were compared with those in sero-survey in 2006. Results A total of 5229 subjects entered the final analysis in 2014. The overall weighed prevalence of anti-HEV IgG was 9.19% (95%CI: 6.18%-12.20%) among natural population in Shandong province, decreased by 19.88% in comparison with that in 2006 sero-survey (11.47%,95%CI: 8.92%-14.02%). The prevalence increased with age increasing(χ2trend=288.11,P<0.001)in 2014, which was similar to the result in 2006 sero-survey. Except for 1-4 years old group, the prevalence of anti-HEV IgG in the other age groups were lower than it in the corresponding groups in 2006. The prevalence of anti-HEV IgG in urban (8.19%, 95%CI:0.00-22.23%), rural areas (9.69%, 95%CI:4.99%-14.38%), eastern areas (12.70%, 95%CI: 0.00-27.72%), central areas (4.74%, 95%CI: 0.00-9.91%) and western areas (9.32%, 95%CI:0.69%-17.94%) in 2014 were all lower than the corresponding prevalences (11.39%, 95%CI: 8.17%-14.62%; 11.92%, 95%CI: 8.75%-15.08%; 22.77%, 95%CI: 14.99%-30.55%; 7.97%, 95%CI: 4.75%-11.20%;10.59%, 95%CI:6.37%-14.82%) in 2006 survey. The prevalence of anti-HEV IgG in coastal areas (16.56%, 95%CI:12.94%-20.18%) and inland areas (7.63%,95%CI:5.16%-10.10%)in 2014 were lower than it in the corresponding areas (28.04%, 95%CI:20.45%-35.64%;9.50%, 95%CI:7.31%-11.70%)in 2006 survey. The prevalence among peasant (11.98%, 95%CI: 8.20%-15.76%), worker (9.68%, 95%CI:4.48%-14.88%), cadre (13.90%, 95%CI: 7.47%-20.33%), service provider (12.26%, 95%CI: 1.80%-22.73%) in 2014 survey were lower than it among the corresponding populations (13.76%, 95%CI:10.15%-17.38%;21.11%, 95%CI:12.67%-29.55%;17.81%, 95%CI:7.63%-28.00%;21.08%, 95%CI:0.03%-42.12%) in 2006 survey. Conclusion The prevalence of anti-HEV IgG has decreased in Shandong province in the recent years, but the epidemiological characteristics found no obvious changes. HEV susceptibility in natural population was generally high. Hepatitis E vaccines were recommended to be used in HEV high-risk population in the province.%目的 分析山东省人群戊型肝炎流行现状,为戊型肝炎防控提供参考.方法 于2014年10月,在山东省12个县(市、区)采用两阶段分层随机抽样方法,选取1~59岁常住人口作为调查对象.首先采用概率比例规模抽样法在调查县(市、区)抽取2个行政村/社区居委会,按照最适分配分层随机抽样方法抽取1~59岁人群,开展问卷调查并采集静脉血标本3~5 ml,共5229名.采用ELISA法检测戊型肝炎病毒(HEV)IgG抗体(抗-HEV IgG);采用抽样权重进行复杂抽样的抗-HEV IgG阳性率点值估计,采用泰勒级数线性法估计抗-HEV IgG阳性率的方差,然后构建估计值的95%CI.通过比较率点值的95%CI进行率的统计学检验.并与2006年山东省戊型肝炎血清流行病学调查结果相比较.结果 5229名调查对象的抗-HEV IgG阳性率为9.19%(95%CI:6.18%~12.20%),较2006年调查结果(11.47%,95%CI:8.92%~14.02%)下降19.88%;抗-HEV IgG阳性率随年龄增加而增高(χ2趋势=288.11,P<0.001),与2006年趋势相同.除1~4岁年龄组抗-HEV IgG与2006年基本持平外,其余各年龄组阳性率均低于2006年相应年龄组.2014年山东省城市人群抗-HEV IgG阳性率(8.19%,95%CI:0.00~22.23%)低于农村(9.69%,95%CI:4.99%~14.38%),东部(12.70%,95%CI:0.00~27.72%)高于中部(4.74%,95%CI:0.00~9.91%)和西部(9.32%,95%CI:0.69%~17.94%),且以上地区抗-HEV IgG阳性率均低于2006年相应地区(11.39%,95%CI:8.17%~14.62%;11.92%,95%CI:8.75%~15.08%;22.77%,95%CI:14.99%~30.55%;7.97%,95%CI:4.75%~11.20%;10.59%,95%CI:6.37%~14.82%).2014年沿海(16.56%,95%CI:12.94%~20.18%)、内陆(7.63%,95%CI:5.16%~10.10%)人群抗-HEV IgG阳性率均低于2006年(28.04%,95%CI:20.45%~35.64%;9.50%,95%CI:7.31%~11.70%).2014年,农民(11.98%,95%CI:8.20%~15.76%)、工人(9.68%,95%CI:4.48%~14.88%)、干部(13.90%,95%CI:7.47%~20.33%)、公共场所服务人员(12.26%,95%CI:1.80%~22.73%),抗-HEV IgG阳性率亦均低于2006年调查相应人群(13.76%,95%CI:10.15%~17.38%;21.11%,95%CI:12.67%~29.55%;17.81%,95%CI:7.63%~28.00%;21.08%,95%CI:0.03%~42.12%).结论 近年来山东省自然人群戊型肝炎阳性率有所下降,但流行特征未发生明显变化;人群易感性较高,应在高危人群中推广使用戊型肝炎疫苗.

摘要： Objective To investigate the performance verification method of the ELISA kit ,and to perform the performance verification of the ELISA kit for hepatitis E virus(HEV) antibody detection to judge whether the used kit could meet the basic requirements of laboratory detection work. Methods The FAME fully automatic enzyme-linked immunity analyzer was used to conduct the ELISA detection,the lowest limit of detection,repeatability,intermediate precision and accuracy by calculation and analysis were compared with the performance indexes provided by the kit instruction ,and the cut off value of kit was verified for judging whether this kit being suitable for the detection of laboratory routine population ,thus for evaluating the performance indexes of the kit. Results In the ELISA detection for HEV,the lowest detection limit of Wantai kit was 0.5 U/mL, which of GBI kit was 1 U/mL;in the precision tests of repeatability,CV of Wantai kit was 4.33% at the weakly positive concentration level(2 U/mL) and 5.84% at the critical value concentration level,which of GBI kit was 5.39% at the weakly positive concentration level(2 U/mL) and 7.82% at the critical value concentration level;in the intermediate precision test, CV of WANTAI kit was 8.89% at the weakly positive concentration level and 12.55% at the critical value concentration level , which of GBI kit was 8.57%at the weakly positive concentration level (2 U/mL) and 12.52%at the critical value concentration level;in the accuracy test,the negative and positive coincidence rates of both kits all reached 100%;in the cutoff value verification test,x+3SD=0.190 in the OD value of WANTAI kit sample,which was less than the cutoff value 0.263 provided by the kits,and x+3SD=0.074 in the OD value of GBI kit sample was 0.074,which was less than the cutoff value 0.150 provided by the kit . Conclusion Both ELISA kits used by the laboratory pass the performance verification ,are suitable for the routine detection and detected groups,which plays an active role for increasing accuracy and quality of laboratory detection.%目的探讨酶联免疫吸附试验（ELISA）检测中试剂盒的性能验证方法，并对该实验室戊型肝炎病毒（HEV）抗体检测中所使用的ELISA试剂盒进行性能验证，以判断所用试剂盒是否能满足实验室检测工作的基本要求。方法使用FAME全自动酶联免疫分析仪进行ELISA检测，通过计算和分析所用试剂盒的最低检出限、重复性、期间精密度、正确度，与试剂盒说明书提供的性能指标进行对比，并对试剂盒的CUTOFF值进行验证，判断其是否适合实验室常规检测人群，以此评价试剂盒的性能指标。结果 HEV ELISA检测中，万泰试剂盒最低检出限为0.5 U/mL，GBI试剂盒最低检出限为1 U/mL；重复性精密度实验中，万泰试剂盒在弱阳性浓度水平（2 U/mL）和临界值浓度水平的变异系数（CV）分别为4.33%和5.84%，GBI试剂盒在弱阳性浓度水平（2 U/mL）和临界值浓度水平的CV分别为5.39%和7.82%；期间精密度实验中，万泰试剂盒在弱阳性浓度水平（2 U/mL）和临界值浓度水平的CV分别为8.89%和12.55%，GBI试剂盒在弱阳性浓度水平（2 U/mL）和临界值浓度水平的CV分别为8.57%和12.52%；正确度验证方面，2种试剂盒的阴阳性符合率都达到100%；CUTOFF值验证实验中，万泰试剂盒检测的样本OD值的x+3SD=0.190，小于试剂盒提供的CUTOFF值0.263，GBI试剂盒检测的样本OD值的x+3SD=0.074，小于试剂盒提供的CUTOFF值0.150。结论实验室所使用的2种试剂盒均通过性能验证，适合实验室日常检测工作和受检人群，对提高实验室检测的准确度和检测质量起到了积极作用。

摘要： 目的 检测戊型肝炎病毒ORF3蛋白对人张氏肝细胞(Changliver,CCL13)增殖及细胞周期的影响.方法 将真核表达载体pDsRed-Monomer-N1-ORF3采用LpofectamineTM2000脂质体法转染CCL13细胞;用MTT比色法测定细胞增殖情况;用流式细胞仪碘化丙啶染色法检测细胞周期;并采用Western-Blot检测细胞周期蛋白的表达.结果 转染pDsRed-Monomer-N1-ORF3的CCL13细胞自第3天开始,增殖受抑(P＜0.01);细胞周期阻滞于G0/G1期;细胞周期蛋白Cyclin Dl及Cyclin E1的表达受抑,Cyclin A2及Cyclin B1蛋白表达量与对照组无差异.结论 戊型肝炎病毒ORF3蛋白可通过抑制细胞周期蛋白Cyclin Dl及Cyclin E1的表达而抑制CCL13细胞的增殖.%Objective To study the effect of hepatitis E virus Open Reading Frame 3 protein on the proliferation and cell cycle of Chang liver cells (CCL13).Methods The pDsRed-Monomer-N1-ORF3 recombinant plasmid was transfected into CCL13 cells via lipofectamine 2 000 reagent,then assayed cell proliferation by MTT assay;Flow cytometric was used to detect cell cycle after dying with PI;and the cell cycle proteins expression were detected by western-blotting.Results pDsRed-Monomer-N1-ORF3 recombinant plasmid was successfully transfected into CCL13 cells,Expression of ORF3 can inhibit the proliferation activity of CCL13 cells from the 3rd day (P ＜ 0.01),and prevent the cell cycle in G0/G1 phase;Western Blot showed expression of cell cycle proteins cyclin D1 and cyclin E1 were decreased in ORF3 group compared with the control group;However,the expression of cyclin A2 and cyclin B1 had no significantly difference in three groups.Conclusions HEV-ORF3 can inhibits the proliferation activity of CCL13 cells by inhibition expression of cell cycle proteins cyclin D1 and cyclin E1.

摘要： 目的 分析浙江省妊娠期妇女HEV感染状况及分子流行特征.方法 采用ELISA对2013年至2015年98 236名妊娠期妇女进行HEV IgM抗体筛查,并利用套式PCR法对IgM抗体阳性样本进行HEV核酸检测,进一步扩增核酸阳性样本的HEV开放阅读框(ORF)2全基因,分析其分子流行病学特征.结果 共检出352例HEV IgM抗体阳性,总阳性率为0.36％,除2例合并HBV感染外,其余均为单纯HEV IgM抗体阳性.核酸检测有3份IgM阳性血清检出HEV特异性核酸片段.进一步分析发现,3株散发性人HEV毒株均属于基因4型HEV.3株样本毒株虽然核苷酸同源性较高,氨基酸同源性更是超过97％,但在进化关系上却不在同一分支内.样本序列与国内外其他地区的毒株相比变异较大,包含1～460位核苷酸和620～870位核苷酸两个高变区,但其氨基酸位点同义替换率与非同义替换率相似,进化压力以中性选择为主.结论 浙江省内妊娠期妇女HEV感染率与已报道的普通人群感染率相似.其中分离的3株HEV毒株均为人畜共患型的HEV 4毒株,变异率较高.%Objective To analyze the hepatitis E virus (HEV) infection status and the molecular characteristics of HEV isolated from pregnant women in Zhejiang Province.Methods Totally 98 236 serum samples collected from pregnant women during the year 2013 to 2015 were tested for HEV IgM by enzyme-linked immunosorbent assay (ELISA) and samples positive for IgM were detected for nucleic acid of HEV by nested polymerase chain reaction (PCR).The whole gene of HEV open reading frame 2 (ORF2) was further amplified and the prevalence was analyzed in nucleic acid-positive samples.Results Three hundred and fifty-two out of 98 236 serum samples were tested positive for HEV IgM,with positive rate of 0.36％.All the samples were simple positive of HEV IgM except for two samples co-infected with hepatitis B virus.HEV specific nucleic acid fragments were detected positive from three serum samples.Further phylogenetic analysis revealed that all the three HEV isolates in this study belonged to HEV genotype 4.Three isolates did not cluster in one branch,although they shared high nucleic acid homology and more than 97 ％ of amino acid homology.Variations were found significantly between sample sequence and other published HEV 4 isolates,including two variable regions found in the ORF2 gene (1-460 nucleotide and 620-870 nucleotide).However,the synonymous and non-synonymous substitutions rates in the two regions were similar,and neutral selection was the main evolutionary pressure.Conclusions HEV infection rate in pregnant women of Zhejiang Province is similar with the published data.The HEV isolates obtained in this study belong to genotype 4 with high variation rate.

摘要： 本文提供了聚凝胺作为细胞培养基中的添加剂在用于产生高滴度戊型肝炎病毒贮备物的方法和用于滴定戊型肝炎病毒的测定中使用的用途。还提供了一种用于高滴度HEV产生的包含聚凝胺的细胞培养基、一种用于确定样品中HEV的存在和/或水平的方法、以及一种使用聚凝胺的HEV滴定测定。

摘要： 本发明涉及一种针对HEV ORF2抗原的单克隆抗体，以及使用竞争ELISA与所述单克隆抗体的抑制率小于50％，优选的小于25％的单克隆抗体。本发明还涉及一种抗体组合物，其中含有至少一种前述单克隆抗体；一种使用双抗体夹心ELISA方法检测HEV抗原的试剂盒，其含有前述抗体组合物；以及利用前述抗体组合物通过双抗体夹心ELISA方法检测样品中HEV抗原的体外方法。本发明还涉及所述抗体组合物用于检测HEV抗原的用途。

摘要： 本发明公开了一种用于双重检测甲型肝炎病毒与戊型肝炎病毒的RT‑RPA‑侧流层析试剂盒，包括：应用于RT‑RAP扩增技术戊型肝炎病毒ORF2基因序列的上游引物、中间探针与下游引物和/或甲型肝炎病毒VP1基因序列的上游引物、中间探针与下游引物，重组酶聚合酶扩增技术所需常规试剂以及测流层析试纸条，所述测流层析试纸条包括加样垫、对照线、1号检测线和/或2号检测线，通过对照线、检测线与引物及探针标记的配合，使用该试剂盒能够快速、灵敏、特异地、在非实验室环境下也可以现场检测检测样本中戊型肝炎病毒ORF2基因和/或甲型肝炎病毒VP1基因。

摘要： 本发明公开了一种基因4型猪戊型肝炎病毒结构区衣壳蛋白基因及其在制备猪戊型肝炎病毒样颗粒中的用途。本发明的经改造后的基因4型猪戊型肝炎病毒结构区衣壳蛋白基因的核苷酸序列如SEQ？ID？NO.1所示，本发明同时公开了该基因表达的重组蛋白及制备病毒样颗粒的方法，具体涉及基因4型猪戊型肝炎病毒结构区衣壳蛋白基因的改造、基因的克隆及其在毕赤酵母中的分泌表达，以及重组蛋白形成病毒样颗粒的制备和扩大培养条件等操作方法的改进等步骤。本发明简单易行，成本较低，实现了基因4型猪戊型肝炎病毒结构区衣壳蛋白在毕赤酵母中稳定分泌表达，表达的重组衣壳蛋白可自包装形成病毒样颗粒，为猪戊型肝炎病毒的抗体检测及亚单位疫苗的研制提供了基础。

摘要： 本文提供了聚凝胺作为细胞培养基中的添加剂在用于产生高滴度戊型肝炎病毒贮备物的方法和用于滴定戊型肝炎病毒的测定中使用的用途。还提供了一种用于高滴度HEV产生的包含聚凝胺的细胞培养基、一种用于确定样品中HEV的存在和/或水平的方法、以及一种使用聚凝胺的HEV滴定测定。

摘要： 本发明涉及一种针对HEV ORF2抗原的单克隆抗体，以及使用竞争ELISA与所述单克隆抗体的抑制率小于50％，优选的小于25％的单克隆抗体。本发明还涉及一种抗体组合物，其中含有至少一种前述单克隆抗体；一种使用双抗体夹心ELISA方法检测HEV抗原的试剂盒，其含有前述抗体组合物；以及利用前述抗体组合物通过双抗体夹心ELISA方法检测样品中HEV抗原的体外方法。本发明还涉及所述抗体组合物用于检测HEV抗原的用途。

摘要： 本发明公开了一种用于双重检测甲型肝炎病毒与戊型肝炎病毒的RT‑RPA‑侧流层析试剂盒，包括：应用于RT‑RAP扩增技术戊型肝炎病毒ORF2基因序列的上游引物、中间探针与下游引物和/或甲型肝炎病毒VP1基因序列的上游引物、中间探针与下游引物，重组酶聚合酶扩增技术所需常规试剂以及测流层析试纸条，所述测流层析试纸条包括加样垫、对照线、1号检测线和/或2号检测线，通过对照线、检测线与引物及探针标记的配合，使用该试剂盒能够快速、灵敏、特异地、在非实验室环境下也可以现场检测检测样本中戊型肝炎病毒ORF2基因和/或甲型肝炎病毒VP1基因。

摘要： 本发明公开了一种可同时检测多种基因型戊型肝炎病毒的方法，该方法针对1型基因型戊型肝炎病毒、2型基因型戊型肝炎病毒、3型基因型戊型肝炎病毒、4型基因型戊型肝炎病毒的基因序列，进行基因序列的综合比对，设计引物和探针；各组探针针对不同型的病毒设计，可以针对HEV type 1，HEV type 3或4，HEV type 1,2,3,4进行检测，达到不同的需求皆能满足地搭配。

摘要： 本发明涉及一种戊型肝炎病毒的蛋白颗粒，具体的讲，涉及戊型肝炎病毒4型ORF2片段的病毒蛋白颗粒，肝炎病毒蛋白颗粒的重组表达载体、宿主细胞、抗体，肝炎病毒蛋白颗粒、抗体和核苷酸序列的应用，表达方法以及其制备方法和应用。本发明的病毒蛋白颗粒的序列具有SEQ NO：1或SEQ NO：3所示序列中至少477位连续的核苷酸序列。

摘要： 提供来自新型的基因型1b的HCV的、自主复制能力优异的亚基因组复制子RNA(核酸)、以及自主复制能力和感染性HCV颗粒产生能力优异的全基因组复制子RNA(核酸)。特别是，提供来自从急性重症丙型肝炎患者体内分离的新型的基因型1b的HCV即NC1株的HCV基因组的亚基因组复制子RNA(核酸)和全基因组复制子RNA(核酸)。